Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity

AIMS: Adalimumab‐adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.). The key objectives of this study were using a population pharmacokinetic (PPK) approach to assess pharmacokinetic (PK) similarity between adalimumab‐adbm and Humira in patients with active r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jia, Eudy‐Byrne, Rena J., Mondick, John, Knebel, William, Jayadeva, Girish, Liesenfeld, Karl‐Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576631/
https://www.ncbi.nlm.nih.gov/pubmed/32363771
http://dx.doi.org/10.1111/bcp.14330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576631/
https://www.ncbi.nlm.nih.gov/pubmed/32363771
http://dx.doi.org/10.1111/bcp.14330

Ejemplares similares